Literature DB >> 19136072

Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.

Piraporn Utachee1, Piyamat Jinnopat, Panasda Isarangkura-Na-Ayuthaya, U Chandimal de Silva, Shota Nakamura, Uamporn Siripanyaphinyo, Nuanjun Wichukchinda, Kenzo Tokunaga, Teruo Yasunaga, Pathom Sawanpanyalert, Kazuyoshi Ikuta, Wattana Auwanit, Masanori Kameoka.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) env genes were cloned from blood samples of HIV-1-infected Thai patients, and 35 infectious CRF01_AE envelope glycoprotein (Env)-recombinant viruses were established. In this report, we examined the neutralization susceptibility of these viruses to human monoclonal antibodies, 2G12, IgG1 b12, 2F5 and 4E10, pooled patient plasma, coreceptor antagonists and fusion inhibitor, T-20. The neutralization susceptibility of CRF01_AE Env-recombinant viruses to 2F5, 4E10, patient plasma, coreceptor antagonists and T-20 varied, while most viruses showed low susceptibility to 2G12 and IgG1 b12. Several dual-tropic viruses showed lower susceptibility to 2F5 and 4E10 than CXCR4- or CCR5-tropic viruses. Neutralization susceptibility of the CRF01_AE Env-recombinant virus to pooled patient plasma was negatively correlated with the length of the V1/V2 region or the number of potential N-linked glycosylation sites in conserved regions of gp120. No correlation was found between the coreceptor usage and neutralization susceptibility of the virus to T-20, whereas several dual-tropic viruses showed higher susceptibility to coreceptor antagonists than CXCR4- or CCR5-tropic viruses. We propose that these CRF01_AE Env-recombinant viruses are useful to further study the molecular mechanism of the susceptibility of CRF01_AE Env to neutralizing antibodies and viral entry inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19136072     DOI: 10.1016/j.micinf.2008.12.008

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  9 in total

1.  Characterization of HIV-1 CRF01_AE env Genes Derived from Recently Infected Indonesian Individuals.

Authors:  Maho Sasaki; Tomohiro Kotaki; Siti Qamariyah Khairunisa; Shingo Tachibana; Youdiil Ophinni; Yoshitake Hayashi; Masanori Kameoka
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-03       Impact factor: 2.205

2.  Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.

Authors:  Piraporn Utachee; Shota Nakamura; Panasda Isarangkura-Na-Ayuthaya; Kenzo Tokunaga; Pathom Sawanpanyalert; Kazuyoshi Ikuta; Wattana Auwanit; Masanori Kameoka
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

3.  Molecular evolution of HIV-1 CRF01_AE Env in Thai patients.

Authors:  Samatchaya Boonchawalit; Duangrat Jullaksorn; Jiraporn Uttiyoung; Amara Yowang; Nongkran Krathong; Sununta Chautrakul; Akifumi Yamashita; Kazuyoshi Ikuta; Amornsak Roobsoong; Sangkom Kanitvittaya; Pathom Sawanpanyalert; Masanori Kameoka
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

4.  Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein.

Authors:  Qi Ron Ng; Kok Keng Tee; James M Binley; Tommy Tong
Journal:  AIDS Res Hum Retroviruses       Date:  2021-06-17       Impact factor: 1.723

5.  Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.

Authors:  Piraporn Utachee; Panasda Isarangkura-na-ayuthaya; Kenzo Tokunaga; Kazuyoshi Ikuta; Naokazu Takeda; Masanori Kameoka
Journal:  Retrovirology       Date:  2014-04-23       Impact factor: 4.602

6.  Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.

Authors:  Sara M O'Rourke; Ruengpung Sutthent; Pham Phung; Kathryn A Mesa; Normand L Frigon; Briana To; Navin Horthongkham; Kay Limoli; Terri Wrin; Phillip W Berman
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

7.  Phyloanatomic characterization of the distinct T cell and monocyte contributions to the peripheral blood HIV population within the host.

Authors:  Brittany RifeMagalis; Samantha L Strickland; Stephen D Shank; Patrick Autissier; Alexandra Schuetz; Pasiri Sithinamsuwan; Sukalaya Lerdlum; James L K Fletcher; Mark de Souza; Jintanat Ananworanich; Victor Valcour; Kenneth C Williams; Sergei L Kosakovsky Pond; Silvia RattoKim; Marco Salemi
Journal:  Virus Evol       Date:  2020-04-27

Review 8.  HIV-1 pseudoviruses constructed in China regulatory laboratory.

Authors:  Jianhui Nie; Weijin Huang; Qiang Liu; Youchun Wang
Journal:  Emerg Microbes Infect       Date:  2019-12-20       Impact factor: 7.163

9.  CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.

Authors:  Sompong Sapsutthipas; Naho Tsuchiya; Panita Pathipavanich; Koya Ariyoshi; Pathom Sawanpanyalert; Naokazu Takeda; Panasda Isarangkura-na-ayuthaya; Masanori Kameoka
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.